We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New - Highly Purified, Cost-Effective CMV Native Antigen for IgM

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "New - Highly Purified, Cost-Effective CMV Native Antigen for IgM"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Native Antigen Company has announced the release of a highly purified Cytomegalovirus (CMV) native antigen.

The antigen has been manufactured in response to the in-vitro diagnostics (IVD) industry’s requirement for a cost effective antigen which can demonstrate a high affinity for not only IgG but more importantly, for IgM.

This latest antigen from NAC’s rapidly increasing portfolio also minimizes cross-reactivity and lot to lot variation.

The company is well equipped to meet an anticipated high volume requirement from IVD manufacturers who major in this field.

Presently, CMV infection is mostly controlled in immune compromised patients by available antiviral drugs, yet it continues to maintain its role as one of the most dangerous infectious agents for the unborn infant.

Primary infection is consistently associated with the presence of a virus specific IgM antibody response.

Use of NAC’s CMV purified native antigen will aid in improving serology based assays for early detection.